RE:RE:RE:RE:RE:RE:RE:RE:RE:PwC sees continuation of US$ 5 to 15 Billion Bio M&A DealsONCY's pelareorep is proving to be synergistic with I/O agents such as immune checkpoint inhibitors (anti-PD-1/PD-L1) and this combination is more effective than either agent alone. Consequently pelareorep has the potential of opening up the PD-1/PD-L1 inhibitor market by a factor of 2x-3x.